Form 4: Nurix CFO Sells NRIX Shares Under 10b5-1 Plan

Nurix Therapeutics' Chief Financial Officer, Hans van Houte, sold 6,284 shares of common stock on November 3, 2025, under a pre-arranged trading plan.

Summary

• Hans van Houte, Chief Financial Officer of Nurix Therapeutics, Inc. (NRIX), reported a sale of common stock.
• The transaction involved the disposition of 6,284 shares of NRIX common stock.
• The shares were sold at a weighted average price of $12.5607 per share.
• The lowest price at which shares were sold was $12.32, and the highest price was $13.14.
• Following this transaction, Hans van Houte beneficially owns 37,592 shares of common stock.
• The sale was executed on November 3, 2025, pursuant to a Rule 10b5-1 trading plan previously adopted by Mr. van Houte.

Sentiment

Score: 5

Explanation: The sale by the Chief Financial Officer, while a disposition of shares, was conducted under a pre-arranged Rule 10b5-1 trading plan, which typically indicates a non-discretionary sale not based on new material information. This mitigates the potential negative sentiment often associated with insider selling.

Negatives

• Chief Financial Officer Hans van Houte disposed of 6,284 shares of common stock, which can sometimes be perceived negatively by the market.

Risks

• Potential for negative market sentiment or investor concern regarding an insider sale, even though it was conducted under a pre-arranged Rule 10b5-1 trading plan.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Management Comments

• The transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.

Industry Context

This insider transaction is a routine disclosure for publicly traded companies and does not inherently reflect broader industry trends. However, investor sentiment in the biotechnology sector can be sensitive to insider activity.

Corporate Governance

Stakeholder Impact

• Shareholders may view the insider sale with caution, although the 10b5-1 plan provides a mitigating explanation for the transaction.

Key Dates

Recommendation

While the Chief Financial Officer sold shares, the transaction was executed under a pre-arranged 10b5-1 trading plan, suggesting it was not based on new material non-public information. This single transaction, representing a portion of the CFO's holdings, does not provide sufficient grounds for a strong buy or sell recommendation, thus a 'hold' is appropriate for existing investors.

Keywords

Nurix Therapeutics, NRIX, Hans van Houte, CFO, Insider Sale, Form 4, 10b5-1 Plan, Stock Transaction, Biotechnology